33th PAGE Meeting

Thessaloniki - Greece
4-6 June, 2025

View abstracts

Home / 2025 – Thessaloniki – Greece / Abstracts

← Back to filters

Abstracts (16)

I-016Kay Hoong Chow

Quantifying natural amyloid plaque accumulation using ADNI, BIOFINDER, A4 and LEARN datasets

Wednesday 10:30-12:00

II-001Ruben Faelens

Predicting Clinical Efficacy Endpoints of a Nipocalimab Phase 3 Study with a Population PKPD Model Developed with Data from a Phase 2 Study in Generalized Myasthenia Gravis

Wednesday 15:30-17:00

II-013Elena Garcia-Montoya

NfL concentration in CSF is a quantitative marker of the rate of neurodegeneration in aging and Huntington’s disease: a semi-mechanistic model-based analysis.

Wednesday 15:30-17:00

II-037Alzahra Hamdan

Item Response Theory Modeling of Digital-Motor Measures as the Primary Outcomes of Rare Degenerative Ataxias

Wednesday 15:30-17:00

II-079Hyun Chul Kim

Population pharmacokinetic-pharmacodynamic analysis of zolpidem to explore sex differences in healthy volunteers

Wednesday 15:30-17:00

II-093Brigitte Lacroix

Exposure-response analysis of minzasolmin in Parkinson’s disease using a lean fit for purpose approach to inform decision making

Wednesday 15:30-17:00

III-012Katie Lynch

Translational Physiologically Based Pharmacokinetic Modelling of Moxifloxacin for Optimizing Treatment of Tuberculous Meningitis

Thursday 9:50-11:45

III-017Vincent Madelain

Translational mPBPK-PD modeling to investigate the determinants of human dose prediction for ASO candidates in CNS diseases

Thursday 9:50-11:45

III-063Marije Otto

Quantification of subjective effects of esketamine and its metabolite esnorketamine in healthy volunteers using a bounded integer modeling approach

Thursday 9:50-11:45

III-070Paraskevi Papakyriakopoulou

Semi-Mechanistic Pharmacokinetic Model of Intranasal Fingolimod hydrochloride Administration in Mice

Thursday 9:50-11:45

III-085Aleksandr Petrov

In Situ, In Vitro, and In Silico Permeability Values as Inputs for Blood-Brain Barrier Penetration Prediction: Impact on Brain Exposure for Passively Diffusing Compounds, with Ethanol as a Case Study

Thursday 9:50-11:45

III-095Luis Quintairos

Population Pharmacokinetic Modeling and Simulation of Tapentadol Bioequivalence: Assessing the Food Effect

Thursday 9:50-11:45

III-102Elena Righetti

Evaluating a-priori fraction unbound predictions against brain homogenate data: Accounting for the experimental bias

Thursday 9:50-11:45

IV-019Hanna Silber Baumann

Confirming pharmacokinetic properties of satralizumab using a bodyweight tiered dosing regimen in LUMINESCE, a phase 3 study for generalized Myasthenia Gravis

Thursday 15:00-16:45

IV-031Ming Sun

LeiCNS-PK3.2: A Physiologically Based Pharmacokinetic Model Incorporating Active Brain Membrane Transport—Insights into Intracellular Exposure of Acyclovir and Ganciclovir Active Metabolites

Thursday 15:00-16:45

IV-065Eline Van Maanen

Joint Exposure-Response Analysis of PET Amyloid Plaque Data from the BACE1 Inhibitor Verubecestat and Amyloid mAbs Trials Enhances the Understanding of Drug Effects

Thursday 15:00-16:45